CYAD — Celyad Oncology SA Cashflow Statement
0.000.00%
Last trade - 00:00- €19.93m
- €16.63m
- €0.19m
Annual cashflow statement for Celyad Oncology SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -17.2 | -26.5 | -40.9 | -8.45 | -5.82 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | -10.3 | -3.08 | 13.3 | -1.1 | -0.147 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -2.02 | 1.43 | -1.84 | -6.45 | -0.159 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -27.7 | -26.6 | -28 | -15.2 | -5.68 |
| Capital Expenditures | -0.319 | -0.393 | -0.123 | -0.934 | -0.118 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.476 | 0.267 | 7.33 | 1.34 | 0.015 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Cash from Investing Activities | 0.157 | -0.126 | 7.2 | 0.407 | -0.103 |
| Financing Cash Flow Items | 6.84 | 4.09 | 4.26 | 0.01 | 3.15 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 5.4 | 39.5 | 3.24 | 9.36 | 2.98 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -22.1 | 12.8 | -17.6 | -5.44 | -2.8 |